Skip to Content

Biotech Briefs

MILESTONE

The U.S. Food and Drug Administration has given Foxborough, MA-based startup Cyberkinetics the green light to begin human tests of its “brain-machine interface” device (see “Brain Power,” TR April 2002). The device, a four-millimeter-square array of 100 tiny electrodes (left) that will be implanted in the brains of up to five quadriplegic people and connected by wires to a nearby computer, promises to let the patients control the computer-and associated communication tools and other aids-using only their brain signals.

METRIC

The biotech industry started off the year with one of its best financing quarters ever, according to a report from Burrill and Company

IPO

Montvale, NJ’s Memory Pharmaceuticals made its debut on the Nasdaq national market in April, with an initial public offering that raised some $35 million in the first day. The company, whose cofounders include Nobel laureates Eric Kandel and Walter Gilbert, is aiming to build on Kandel’s work on the biology of memory to develop treatments for central-nervous-system disorders such as Alzheimer’s disease, Schizophrenia, and age-related memory loss.

ADVANCE

A new vaccine might succeed where cigarette-pack warning labels have failed. Nabi Biopharmaceuticals of Rockville, MD, has completed early human tests of a vaccine aimed at preventing nicotine addiction and helping hooked smokers quit. The trial proved the ability of the vaccine to generate antibodies against nicotine; further tests planned to conclude in the second half of this year will measure the vaccine’s ability to help smokers kick the habit.

FOLLOW-UP

Cambridge, MA-based startup Alnylam Pharmaceuticals filed preliminary papers with the U.S. Securities and Exchange Commission for an initial public offering. Alnylam is one of a handful of companies that have sprung up in recent years around RNA interference (RNAi), in which small pieces of RNA are used to turn specific genes off-to block the progress of a disease, for example (see “The RNA Cure?TR November 2003). Alnylam’s aim is to develop RNAi therapeutics for ailments such as age-related macular degeneration, a leading cause of vision loss in older people, and Parkinson’s disease.

ACQUISITION

In a stock deal worth $9.5 billion, Fairfield, CT-based General Electric has acquired Amersham, a British medical-diagnostics and life sciences firm. Among the benefits that GE executives expect: faster development of molecular imaging and personalized medicine.

FORECAST

The nonprofit International Service for the Acquisition of Agri-Biotech Applications (ISAAA) predicts that, despite debate, genetically modified crops will blossom. The ISAAA projects the crops’ global market value to reach $5 billion by next year; within the next five years, it predicts, 10 million farmers in at least 25 countries will plant 100 million hectares of biotech crops.

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway

Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.